Aveo Pharmaceuticals Inc AVEO:NASDAQ

Last Price$3.86Cboe Real-Time Last Sale as of 10:43AM ET 1/18/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.09(2.28%)
Bid (Size)$3.85 (100)
Ask (Size)$3.87 (100)
Day Low / High$3.83 - 3.95
Volume29.5 K

View Biotechnology IndustryPeer Comparison as of 01/18/2022


Aveo Pharmaceuticals Inc ( NASDAQ )

Price: $3.86
Change: -0.09 (2.28%)
Volume: 29.5 K
10:43AM ET 1/18/2022

La Jolla Pharmaceutical Co ( NASDAQ )

Price: $4.77
Change: -0.15 (3.05%)
Volume: 21.5 K
10:36AM ET 1/18/2022

AquaBounty Technologies Inc ( NASDAQ )

Price: $1.83
Change: -0.01 (0.54%)
Volume: 201.9 K
10:38AM ET 1/18/2022

Synlogic Inc ( NASDAQ )

Price: $2.02
Change: -0.03 (1.46%)
Volume: 16.2 K
10:36AM ET 1/18/2022

Opiant Pharmaceuticals Inc ( NASDAQ )

Price: $27.62
Change: +0.55 (2.03%)
Volume: 25.6 K
10:37AM ET 1/18/2022

Read more news Recent News

AVEO Oncology Working With NiKang Therapeutics to Develop Combination Therapy for Kidney Cancer
11:22AM ET 1/05/2022 MT Newswires

AVEO Oncology (AVEO) and NiKang Therapeutics said Wednesday they are working together to develop a potential treatment for advanced clear cell renal cell...

Aveo Pharmaceuticals, Merck KgaA Enter Supply Deal for Head, Neck Cancer Trial
10:35AM ET 1/04/2022 MT Newswires

Aveo Pharmaceuticals (AVEO) said Tuesday it entered a clinical trial collaboration and supply agreement with Merck KgaA to evaluate ficlatuzumab in...

AVEO Pharmaceuticals Names Jeb Ledell as Operations Chief
7:39AM ET 12/01/2021 MT Newswires

AVEO Pharmaceuticals (AVEO) said Wednesday it has appointed Jeb Ledell as chief operating officer. Ledell previously served as operations chief at...

-- Earnings Flash (AVEO) AVEO ONCOLOGY Posts Q3 Revenue $15.2M, vs. Street Est of $13.8M
4:10PM ET 11/08/2021 MT Newswires


Company Profile

Business DescriptionAVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA. View company web site for more details
Address30 Winter Street
Boston, Massachusetts 02108
Number of Employees17
Recent SEC Filing12/03/20213
President, Chief Executive Officer & DirectorMichael P. Bailey
Chief Operating OfficerJebediah Ledell
Chief Financial OfficerErick J. Lucera
Vice President-Information TechnologyMatthew Coulter

Company Highlights

Price Open$3.92
Previous Close$3.95
52 Week Range$3.76 - 18.24
Market Capitalization$132.7 M
Shares Outstanding34.4 M
SectorHealth Technology
Next Earnings Announcement03/15/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.98
Beta vs. S&P 500N/A
Revenue$5.4 M
Net Profit Margin-225.54%
Return on Equity-105.10%

Analyst Ratings as of 11/06/2020

Consensus RecommendationConsensus Icon
Powered by Factset